Cullot, G. http://orcid.org/0000-0003-3925-705X
Boutin, J. http://orcid.org/0000-0001-9948-4129
Fayet, S.
Prat, F.
Rosier, J.
Cappellen, D. http://orcid.org/0000-0002-9634-2595
Lamrissi, I.
Pennamen, P. http://orcid.org/0000-0002-0363-9884
Bouron, J.
Amintas, S.
Thibault, C. http://orcid.org/0000-0002-9420-4180
Moranvillier, I.
Laharanne, E.
Merlio, J. P. http://orcid.org/0000-0002-0305-0850
Guyonnet-Duperat, V.
Blouin, J. M.
Richard, E.
Dabernat, S.
Moreau-Gaudry, F. http://orcid.org/0000-0003-1813-3939
Bedel, A.
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-21-CE18-0002-01)
AFM-Téléthon (24136)
Article History
Received: 22 August 2022
Accepted: 22 June 2023
First Online: 10 July 2023
Competing interests
: S.F., A.B., and F.M.G declared a patent application EP23305760 filed on May 13th 2023 and claims the use of Palbociclib to prevent genotoxicity induced by nuclease. The remaining authors declare no competing interests.